We are live on ! Find out more
BLTE

Belite Bio
BLTE

17 hedge funds and large institutions have $7.1M invested in Belite Bio in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 2

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

143% more funds holding

Funds holding: 7 → 17 (+10)

124% more capital invested

Capital invested by funds: $3.17M → $7.1M (+$3.93M)

0.2% more ownership

Funds ownership: 0.37% → 0.56% (+0.2%)

Holders
17
Holders Change
+10
Holders Change %
+142.86%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.38M
2
Morgan Stanley
Morgan Stanley
New York
+$845K
3
CSS
Cubist Systematic Strategies
Connecticut
+$649K
4
Marshall Wace
Marshall Wace
United Kingdom
+$615K
5
JP Morgan Chase
JP Morgan Chase
New York
+$548K

Top Sellers

Rank Fund Capital Flow
1
AWS
Atria Wealth Solutions
New York
-$2.36M
2
UBS Group
UBS Group
Switzerland
-$20.6K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$16.6K

BLTE Hedge Fund Activity: Q4 2023 in Review

17 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q4 2023, worth a combined $7.1M — up 124% from $3.17M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BLTE positions and 2 closed out — a net gain of 10 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.38M. The largest seller was Atria Wealth Solutions, exiting entirely with an estimated $2.36M sold.

  • 17 institutional investors held Belite Bio (BLTE) as of Q4 2023, up from 7 in Q3 2023.
  • Funds reported $7.1M of Belite Bio stock for Q4 2023, up 124% quarter-over-quarter.
  • 12 funds opened new Belite Bio positions in Q4 2023 and 2 closed out, a net change of +10 holders.
  • The largest Belite Bio buyer in Q4 2023 was Armistice Capital, an estimated $1.38M added.
  • The largest Belite Bio seller in Q4 2023 was Atria Wealth Solutions, an estimated $2.36M sold.

Based on aggregated 13F filings for Q4 2023.